Nicolas Marcoux

1.1k total citations
15 papers, 58 citations indexed

About

Nicolas Marcoux is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Nicolas Marcoux has authored 15 papers receiving a total of 58 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Nicolas Marcoux's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Nicolas Marcoux is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Nicolas Marcoux collaborates with scholars based in Canada, United States and France. Nicolas Marcoux's co-authors include Lecia V. Sequist, Zofia Piotrowska, Rebecca J. Nagy, Richard B. Lanman, Antoine Desîlets, A. John Iafrate, Aaron N. Hata, Catalin Mihalcioiu, Stephen V. Liu and Sara E. Stevens and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

Nicolas Marcoux

13 papers receiving 57 citations

Peers

Countries citing papers authored by Nicolas Marcoux

Since Specialization

Citations

This map shows the geographic impact of Nicolas Marcoux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Marcoux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Marcoux more than expected).

Fields of papers citing papers by Nicolas Marcoux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Marcoux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Marcoux. The network helps show where Nicolas Marcoux may publish in the future.

Co-authorship network of co-authors of Nicolas Marcoux

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Marcoux. A scholar is included among the top collaborators of Nicolas Marcoux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Marcoux. Nicolas Marcoux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report 2025 ·Current Oncology ·(unknown), Éric Lévesque, Vincent Castonguay, Nicolas Marcoux, (unknown), Martin Veilleux	0
2	1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate) 2024 ·Annals of Oncology ·Arielle Elkrief, Siddhartha P. Duttagupta, (unknown), Nicolas Marcoux, Antoine Desîlets, Meriem Messaoudene, Catalin Mihalcioiu, Sylvère Durand, (unknown), (unknown), Sioned Owen, (unknown), John Lenehan, Seema Nair Parvathy, (unknown), (unknown), Guido Kroemer, Michael H. Silverman, Saman Maleki Vareki, Bertrand Routy	11
3	Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process 2024 ·Current Oncology ·Anthony Brade, Houda Bahig, Andrea Bezjak, Rosalyn A. Juergens, (unknown), Nicolas Marcoux, Barbara Melosky, Devin Schellenberg, Stephanie Snow	1
4	Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Frédéric Pouliot, Fred Saad, Étienne Rousseau, Patrick O. Richard, (unknown), Stephan Probst, Éric Lévesque, Vincent Castonguay, Nicolas Marcoux, Daniel Juneau, Michele Lodde, Jean‐Baptiste Lattouf, François-Alexandre Buteau, Zineb Hamilou, Michel Pavic, (unknown), Guillaume F. Bouvet, Amélie Têtu, Brigitte Guérin, Jean‐Mathieu Beauregard	5
5	Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study 2023 ·Cancer Medicine ·(unknown), Tushar Vora, Jonathan Noujaim, Nicolas Marcoux, Sarah Cohen‐Gogo, Thierry Alcindor, Caroline L. Holloway, (unknown), Hatim Karachiwala, (unknown), (unknown), Sylvia Cheng, Shantanu Banerji, Sapna Oberoi, Xiaolan Feng, Alannah Smrke, Christine Simmons, Albiruni Abdul Razak, Abha A. Gupta	7
6	Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study. 2023 ·Journal of Clinical Oncology ·Frédéric Pouliot, Fred Saad, Patrick O. Richard, Stephan Probst, Étienne Rousseau, Éric Lévesque, Vincent Castonguay, Nicolas Marcoux, Michele Lodde, Jean‐Baptiste Lattouf, François-Alexandre Buteau, Daniel Juneau, Zineb Hamilou, Michel Pavic, (unknown), (unknown), Guillaume F. Bouvet, Amélie Têtu, Brigitte Guérin, Jean‐Mathieu Beauregard, (unknown)	1
7	Real-world experience of tyrosine kinase inhibitors in patients (pt) with recurrent bone tumours (BT): A CanSaRCC study. 2022 ·Journal of Clinical Oncology ·Tushar Vora, (unknown), Jonathan Noujaim, Nicolas Marcoux, Thierry Alcindor, Hatim Karachiwala, (unknown), Furqan Shaikh, Albiruni Ryan Abdul Razak, Abha A. Gupta	1
8	Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI). 2019 ·Journal of Clinical Oncology ·Zofia Piotrowska, (unknown), Mandeep K. Banwait, Nicolas Marcoux, Meghan J. Mooradian, Ibiayi Dagogo‐Jack, (unknown), Rebecca S. Heist, Alice T. Shaw, Justin F. Gainor, Lecia V. Sequist	0
9	MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement 2018 ·Journal of Thoracic Oncology ·Zofia Piotrowska, Hideko Isozaki, Jochen K. Lennerz, Subba R. Digumarthy, Justin F. Gainor, Nicolas Marcoux, Mandeep K. Banwait, Dora Dias‐Santagata, A. John Iafrate, Mari Mino–Kenudson, Rebecca J. Nagy, Richard B. Lanman, Erica N Evans, Corinne Clifford, Beni B. Wolf, Aaron N. Hata, Lecia V. Sequist	1
10	MS18.03 Treatment of SCLC transformed from EGFR Mutant Adenocarcinoma 2018 ·Journal of Thoracic Oncology ·Nicolas Marcoux	1
11	Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC). 2018 ·Journal of Clinical Oncology ·Nicolas Marcoux, Scott Gettinger, Grainne M. O’Kane, Kathryn C. Arbour, Joel W. Neal, Hatim Husain, Tracey L. Evans, Julie R. Brahmer, Alona Muzikansky, Philip Bonomi, Salvatore A. Del Prete, Anna Wurtz, Anna F. Farago, Dora Dias‐Santagata, Mari Mino–Kenudson, Helena A. Yu, Heather A. Wakelee, Frances A. Shepherd, Zofia Piotrowska, Lecia V. Sequist	1
12	Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC. 2018 ·Journal of Clinical Oncology ·Zofia Piotrowska, Stephen V. Liu, Alona Muzikansky, Nicolas Marcoux, Mandeep K. Banwait, Sara E. Stevens, Kelly Goodwin, (unknown), Jennifer Ackil, (unknown), Rebecca S. Heist, (unknown), Justin F. Gainor, Aaron N. Hata, Alice T. Shaw, Lecia V. Sequist	10
13	Clinical outcomes for EGFR-mutant adenocarcinomas (AC) that transform to small cell lung cancer (SCLC) 2017 ·Annals of Oncology ·Nicolas Marcoux, Zofia Piotrowska, Anna F. Farago, Aaron N. Hata, Meghan J. Mooradian, Benjamin J. Drapkin, Alona Muzikansky, Scott Gettinger, Mari Mino–Kenudson, Lecia V. Sequist	1
14	OA 09.01 Characterizing the Genomic Landscape of EGFR C797S in Lung Cancer Using ctDNA Next-Generation Sequencing 2017 ·Journal of Thoracic Oncology ·Zofia Piotrowska, Rebecca J. Nagy, Stephen R. Fairclough, Richard B. Lanman, Nicolas Marcoux, Scott Gettinger, Taofeek K. Owonikoko, (unknown), Lecia V. Sequist	10
15	Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer–Transformed EGFR Mutant Non–Small-Cell Lung Cancer 2017 ·JCO Precision Oncology ·Meghan J. Mooradian, Zofia Piotrowska, Benjamin J. Drapkin, Dora Dias‐Santagata, Nicolas Marcoux, Konstantinos Arnaoutakis, Rebecca J. Nagy, Richard B. Lanman, A. John Iafrate, Anna F. Farago, Mari Mino–Kenudson, Aaron N. Hata, Lecia V. Sequist	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact